Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer
出版年份 2022 全文链接
标题
Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer
作者
关键词
-
出版物
Science Advances
Volume 8, Issue 20, Pages -
出版商
American Association for the Advancement of Science (AAAS)
发表日期
2022-05-21
DOI
10.1126/sciadv.abk2746
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Cooperative targeting of immunotherapy-resistant melanoma and lung cancer by an AXL-targeting antibody-drug conjugate and immune checkpoint blockade
- (2021) Julia Boshuizen et al. CANCER RESEARCH
- Acquired cancer cell resistance to T cell bispecific antibodies and CAR T targeting HER2 through JAK2 down-modulation
- (2021) Enrique J. Arenas et al. Nature Communications
- ONO-7475, a novel AXL inhibitor, suppresses the adaptive resistance to initial EGFR-TKI treatment in EGFR-mutated non-small lung cancer
- (2020) Naoko Okura et al. CLINICAL CANCER RESEARCH
- Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade
- (2020) Fara Brasó-Maristany et al. Nature Communications
- ERBB2 mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer
- (2020) Gaia Griguolo et al. Cancers
- FGFR4 regulates tumor subtype differentiation in luminal breast cancer and metastatic disease
- (2020) Susana Garcia-Recio et al. JOURNAL OF CLINICAL INVESTIGATION
- Axl and Mertk receptors cooperate to promote breast cancer progression by combined oncogenic signaling and evasion of host anti-tumor immunity
- (2020) Viralkumar Davra et al. CANCER RESEARCH
- TP-0903 is active in models of drug-resistant acute myeloid leukemia
- (2020) Jae Yoon Jeon et al. JCI Insight
- AXL confers intrinsic resistance to osimertinib and advances the emergence of tolerant cells
- (2019) Hirokazu Taniguchi et al. Nature Communications
- HER2-enriched subtype and ERBB2 expression in HER2-positive breast cancer treated with dual HER2 blockade
- (2019) Aleix Prat et al. JNCI-Journal of the National Cancer Institute
- AXL degradation in combination with EGFR-TKI can delay and overcome acquired resistance in human non-small cell lung cancer cells
- (2019) Donghwa Kim et al. Cell Death & Disease
- AXL Targeting Overcomes Human Lung Cancer Cell Resistance to NK- and CTL-Mediated Cytotoxicity
- (2019) Stéphane Terry et al. Cancer Immunology Research
- A novel AXL chimeric antigen receptor endows T cells with anti-tumor effects against triple negative breast cancers
- (2018) Jing Wei et al. CELLULAR IMMUNOLOGY
- Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors
- (2018) Julia Boshuizen et al. NATURE MEDICINE
- The Receptor Tyrosine Kinase AXL Is Required at Multiple Steps of the Metastatic Cascade during HER2-Positive Breast Cancer Progression
- (2018) Marie-Anne Goyette et al. Cell Reports
- Elevated WBP2 expression in HER2-positive breast cancers correlates with sensitivity to trastuzumab-based neo-adjuvant therapy:A Retrospective and Multicentric Study
- (2018) Shin-Ae Kang et al. CLINICAL CANCER RESEARCH
- New insights into the mechanisms of epithelial–mesenchymal transition and implications for cancer
- (2018) Anushka Dongre et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial
- (2017) Antonio Llombart-Cussac et al. LANCET ONCOLOGY
- Key Roles of AXL and MER Receptor Tyrosine Kinases in Resistance to Multiple Anticancer Therapies
- (2017) Marie Schoumacher et al. Current Oncology Reports
- Molecular Pathways: AXL, a Membrane Receptor Mediator of Resistance to Therapy
- (2016) M. Scaltriti et al. CLINICAL CANCER RESEARCH
- Therapeutic Activity of Anti-AXL Antibody against Triple-Negative Breast Cancer Patient-Derived Xenografts and Metastasis
- (2016) Wilhem Leconet et al. CLINICAL CANCER RESEARCH
- The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtype-specific therapeutic target for ovarian cancer
- (2016) J. Antony et al. Science Signaling
- Reduced Proteolytic Shedding of Receptor Tyrosine Kinases Is a Post-Translational Mechanism of Kinase Inhibitor Resistance
- (2016) M. A. Miller et al. Cancer Discovery
- Gas6/Axl Axis Contributes to Chemoresistance and Metastasis in Breast Cancer through Akt/GSK-3β/β-catenin Signaling
- (2016) Cun Wang et al. Theranostics
- The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtype-specific therapeutic target for ovarian cancer
- (2016) J. Antony et al. Science Signaling
- AXL Mediates Resistance to PI3Kα Inhibition by Activating the EGFR/PKC/mTOR Axis in Head and Neck and Esophageal Squamous Cell Carcinomas
- (2015) Moshe Elkabets et al. CANCER CELL
- Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia
- (2015) I-K Park et al. LEUKEMIA
- Patterns of HER2 Gene Amplification and Response to Anti-HER2 Therapies
- (2015) Rocio Vicario et al. PLoS One
- Mesenchymal Cancer Cell-Stroma Crosstalk Promotes Niche Activation, Epithelial Reversion, and Metastatic Colonization
- (2015) Yaiza del Pozo Martin et al. Cell Reports
- Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma
- (2014) Judith Müller et al. Nature Communications
- Molecular Mechanism of 17-Allylamino-17-demethoxygeldanamycin (17-AAG)-induced AXL Receptor Tyrosine Kinase Degradation
- (2013) Gnana Prakasam Krishnamoorthy et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Vimentin as a poor prognostic factor for triple-negative breast cancer
- (2013) Nami Yamashita et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- AXL and MET crosstalk to promote gonadotropin releasing hormone (GnRH) neuronal cell migration and survival
- (2013) Smita Salian-Mehta et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- AXL induces epithelial-to-mesenchymal transition and regulates the function of breast cancer stem cells
- (2013) M K Asiedu et al. ONCOGENE
- The Receptor AXL Diversifies EGFR Signaling and Limits the Response to EGFR-Targeted Inhibitors in Triple-Negative Breast Cancer Cells
- (2013) A. S. Meyer et al. Science Signaling
- An Epithelial-Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance
- (2012) L. A. Byers et al. CLINICAL CANCER RESEARCH
- Axl is essential for VEGF-A-dependent activation of PI3K/Akt
- (2012) Guo-Xiang Ruan et al. EMBO JOURNAL
- Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
- (2012) Zhenfeng Zhang et al. NATURE GENETICS
- Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31
- (2011) Edith A. Perez et al. JOURNAL OF CLINICAL ONCOLOGY
- Mechanisms of resistance to anti-human epidermal growth factor receptor 2 agents in breast cancer
- (2010) Toru Mukohara CANCER SCIENCE
- Inhibition of Mer and Axl Receptor Tyrosine Kinases in Astrocytoma Cells Leads to Increased Apoptosis and Improved Chemosensitivity
- (2010) A. K. Keating et al. MOLECULAR CANCER THERAPEUTICS
- Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer
- (2010) K Vuoriluoto et al. ONCOGENE
- An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients
- (2009) Balazs Györffy et al. BREAST CANCER RESEARCH AND TREATMENT
- Novel Mechanism of Lapatinib Resistance in HER2-Positive Breast Tumor Cells: Activation of AXL
- (2009) L. Liu et al. CANCER RESEARCH
- Epithelial-Mesenchymal Transitions in development and disease: old views and new perspectives
- (2009) M. Angela Nieto INTERNATIONAL JOURNAL OF DEVELOPMENTAL BIOLOGY
- Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival
- (2009) C. Gjerdrum et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started